PR1 Leukemia Peptide Vaccine
DRACPC ID DRACPC0097
Active Ingredients PR1 Leukemia Peptide Vaccine
Description A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis.
Synonyms PR1: 169-177; Leukemia Peptide Vaccine, PR1; PR1 Leukemia Peptide Vaccine; Proteinase 3:PR1 Peptide
Type Biotech
Disease Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula C45H79N11O15
Molecular Weight 1014.2
Active Sequence VLQELNVTV
Sequence Length 9
Modification None
IUPAC Name (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
InChI InChI=1S/C45H79N11O15/c1-19(2)16-27(40(65)52-29(18-31(47)59)41(66)54-34(22(7)8)43(68)56-36(24(11)57)44(69)55-35(23(9)10)45(70)71)51-38(63)26(13-15-32(60)61)49-37(62)25(12-14-30(46)58)50-39(64)28(17-20(3)4)53-42(67)33(48)21(5)6/h19-29,33-36,57H,12-18,48H2,1-11H3,(H2,46,58)(H2,47,59)(H,49,62)(H,50,64)(H,51,63)(H,52,65)(H,53,67)(H,54,66)(H,55,69)(H,56,68)(H,60,61)(H,70,71)/t24-,25+,26+,27+,28+,29+,33+,34+,35+,36+/m1/s1
InChI_Key WOACUGNMTZAEJZ-GXLXRQKGSA-N
SMILES CC(C[C@@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)CC(N)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)N)=O)CC(C)C)=O)CCC(N)=O)=O)CCC(O)=O)=O)C
External Codes
PubChem CID 11672494
DrugBank Accession Number DB15276
NCI Thesaurus Code C2235
UNII 54XUF2TZ7G GSRS
CAS 182253-77-6
Drug approval
Drug indication
Investigated for use/treatment in Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00488592 | Efficacy of Peptide (WT1) and Peptide(PRI) Vaccination for Patients With Low Risk Myeloid Malignancies | Myelodysplastic Syndrome (MDS); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML) | Phase 2 | Treatment |
| NCT00004918 | A Phase I/II Study of PR1 (NSC 698102) Human Leukemia Peptide Vaccine With Montanide ISA 51 (NSC 675756) or Montanide ISA 51 VG (NSC 737063) Adjuvant | Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Chronic Phase Chronic Myelogenous Leukemia; Previously Treated Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Relapsing Chronic Myelogenous Leukemia | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
